comparemela.com

Latest Breaking News On - Mersana dolaflexin - Page 1 : comparemela.com

Mersana Therapeutics Announces Appointment of Mohan Bala, Ph D , as SVP, Strategic Product Planning & Program LeadershipBrian DeSchuytner named SVP and Chief Financial Officer

Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program LeadershipBrian DeSchuytner named SVP and Chief Financial Officer - read this article along with other careers information, tips and advice on BioSpace

Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer

Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer April 26, 2021 08:00 ET | Source: Mersana Therapeutics, Inc. Mersana Therapeutics, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer. “With our UPLIFT strategy now underway for UpRi and our growing pipeline of product candidates derived from our innovative ADC platforms, we are thrilled to have Alejandra join the team at this time of immense growth,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. “Alejand

Mersana Therapeutics Announces Appointment of Allene Diaz to Board of Directors

Published: Mar 11, 2021 CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) Mersana Therapeutics, Inc.. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Allene Diaz to its board of directors. “Allene’s breadth of knowledge in strategic product planning, portfolio management and commercialization of cancer therapeutics will be invaluable to Mersana as we focus on building UpRi as a foundational therapy for the treatment of ovarian cancer and building out our maturing pipeline of ADC candidates. With our growing portfolio of product candidates, the strategic choices we make to create differentiated product labeling and positioning are critical to our vision of discovering and developing life-changing ADC therapies for patients fighting cancer. We are excited to benefit from Allene’s experienc

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.